▶주메뉴 바로가기
▶본문 바로가기
The Ministry of Food and Drug Safety on Oct. 16 ordered Medytox to withdraw and dispose of the entire batch of its botulinum toxin Meditoxin produced for exports. The problematic products were produ...
Daewoong Pharmaceutical announced Oct. 16 it has launched its botulinum toxin under the name Nuceiva in Canada. It is the first South Korean company to enter the Canadian market with a botulinum tox...
South Korea’s Supreme Court announced on Oct. 16 that it has approved a request by Samsung BioLogics to suspend the execution of penalties by the financial watchdog on Oct. 11. The court’s recent ...
Daewoong Pharmaceutical on Oct. 7 denied allegations by Medytox that it stole manufacturing secrets, including its Hall A Hyper strain, to develop its botulinum toxin Nabota. “Medytox is saying that...
South Korean drugmaker Daewoong Pharmaceutical said Oct, 2 it has won approval from European authorities for the sale of its botulinum toxin product. The European Commission accepted Daewoong’s a...
Samsung BioLogics has won a lawsuit against Switzerland-based Lonza to nullify its patents involving its cell line development technology in South Korea, according to sources Oct. 1. The court noted...
South Korean biotech firm Genexine announced on Sept. 27 that it has signed a contract with the Thai company KinGen Holdings to establish a 50:50 joint venture named KinGen Biotech. KinGen Holdings ...
Celltrion Healthcare on Sept. 27 announced its decision to expand sales in the Middle East. He company has got approval to exclusively supply Remsima, its version of Johnson & Johnson’s Remicade fro...
Celltrion Group on Sept. 20 announced that European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended giving sales approval for Remsima SC. CHMP is responsible for pr...
Medytox has participated in the seed-funding round of US startup LifeSprout, according to industry sources on Sept. 16. Although the Korean company declined to confirm the specific amount that it ha...
Korean pharmaceutical companies are making inroads into the Central and South American markets, betting on their steady growth. Samsung Bioepis, Celltrion Healthcare, Boryung Pharmaceutical, CJ Heal...
South Korean biopharmaceutical firm Celltrion announced Sept. 10 that its breast cancer biosimilar has been approved for sales in Canada. The regulatory body Health Canada has approved the data from...
South Korea’s Supreme Court has approved a grace period for Samsung BioLogics to defer the implementation of penalties imposed by the financial authorities by up to 30 days, the biopharma firm said...
Celltrion Group expects to receive approval for biosimilar Remsima SC from European authorities for sales before the end of this year, founder and Chairman Seo Jung-jin said at a bio conference on A...
South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial of its drug candidate BR2002 The phase 1...
NH NongHyup launches biometric boarding service
Ex-presidential adviser named head of Korea’s sovereign wealth fund
KakaoBank’s Q1 net profit jumps 150%
KB Asset raises W1tr for AMP Capital’s infra debt funds
Climate response fund to be set up in 2022 to bolster renewable energy transition
Middle-income households see sharpest drop in spending
MMAA hires ex-Lotte insurance CIO
Real estate fiasco sidelines Moon’s income-led growth drive
May 19, 2021
